Know Cancer

forgot password

The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells

18 Years
Not Enrolling
Colorectal Cancer

Thank you

Trial Information

The Effect of Plant Phenolic Compounds on Human Colon Epithelial Cells


- Determine the response of the colonic epithelium in normal volunteers at average or
above average risk of colon cancer, when given short term treatment with plant
phenolics such as curcumin, rutin, and quercetin.

- Compare the colonic mucosal response to the plant phenolics with their response to
sulindac in order to evaluate whether they share common mechanisms for colon cancer

- Determine the lowest optimal dose for each of the three plant phenolics that is
effective in modulating biomarkers of colon epithelial cell turnover and, therefore,
potentially inhibiting colon cancer development.

- Assess the response of the colonic epithelium to curcumin in volunteers at average risk
of colon cancer development.

OUTLINE: This is a randomized, controlled, two part, single institution study. Patients in
Part B are randomized by gender.

All patients undergo flexible sigmoidoscopic exam.

- Part A: Patients, in cohorts of 5-10, receive one of the following five treatments in
addition to the control diet: nothing (arm I), oral sulindac twice a day (arm II), oral
rutin at 1 of 3 doses twice a day (arms III, IV, and V), oral quercetin at 1 of 3 doses
twice a day (arms V, VI, and VII), or at 1 of 3 doses oral curcumin twice a day (arms
VIII, IX, and X). Patients are first randomized to the highest doses of rutin,
quercetin, and curcumin and then lower doses may be given in order to determine the
minimally effective dose. Treatment is continued for 6-10 weeks.

- Part B: Patients are randomized to receive the control diet only (arm I) or the control
diet plus oral curcumin twice a day (arm II) for 6-10 weeks.

Patients are followed every 2 weeks.

PROJECTED ACCRUAL: There will be 130 patients (110 in Part A and 20 in Part B) accrued into
this study.

Inclusion Criteria


- Individuals at average risk (Parts A and B) or above average risk (Part A only) for
development of colon cancer

- Average risk individuals defined as:

- No history of colon adenomas

- No strong family history of colon polyps or cancer

- Above average risk individuals defined as:

- History of one or more sporadic adenomatous polyps at least 0.5 cm in size
(either tubular, tubulovillous, or villous adenomas)

- Have had polypectomy or refused this procedure

- No significant family history of adenomatous polyps, colon cancer, or
hereditary nonpolyposis colorectal cancer or other hereditary colon cancer

- Polyps should not have had a focus of adenocarcinoma within them

- No history of gastrointestinal cancer outside of the large bowel

- No other gastrointestinal mucosal epithelial disease (e.g., Barrett's esophagus,
chronic or recurrent peptic ulcer disease, celiac sprue, or other disorders of
nutrient absorption)

- No significant asymptomatic lesions on flexible sigmoidoscopy, such as inflammation,
premalignancy or malignancy



- 18 and over

Performance status:

- Not specified

Life expectancy:

- Not specified


- No platelet or coagulation abnormalities

- No personal or family history of a bleeding disorder

- Hematopoietic concentration must not be due to significant acute or chronic disorder


- No liver disease


- No renal insufficiency


- No uncontrolled hypertension

- No chronic congestive heart failure

- No history of endocarditis

- No history of rheumatic fever

- No cardiac valve prostheses

- No mitral valve prolapse that requires antibiotic prophylaxis


- HIV negative

- No gout

- No pancreatitis

- No other chronic viral infection

- No significant acute or uncontrolled chronic medical illness

- Generally non-smoking (no more than 4 cigarettes per week, i.e., not daily smokers)

- Must abstain from smoking for at least 1 month prior to enrolling in the study

- No alcohol consumption of greater than 2 glasses of wine or beer per day

- Normal weight (90-120% of optimum body weight) and body habitus

- No change in weight within 5-10% of body weight within the past year

- No history of inflammatory bowel disease (either ulcerative colitis or Crohn's
disease )

- No hearing or equilibrium disorders

- No other prior malignancy except resected carcinoma in situ of the cervix or
nonmelanoma skin cancer

- No allergies to sulindac or tartrazine dyes or prior severe adverse reactions to
nonsteroidal antiinflammatory drugs (asthma, gastrointestinal bleeding, or renal

- No potential allergy to curcumin, quercetin, or rutin

- No gastrointestinal bleeding

- Not institutionalized, mentally disabled, or incarcerated

- No unusually high intake of stored micronutrients or high doses of supplemental
calcium or folate

- Not pregnant or nursing


Biologic therapy:

- Not specified


- Not specified

Endocrine therapy:

- Not specified


- Not specified


- Not specified


- No concurrent coumadin

- No chronic use of nonsteroidal antiinflammatory drugs (unless they can be stopped for
3 months)

- No other putative colon cancer chemoprevention agents (unless they can be stopped for
3 months)

Type of Study:


Study Design:

Allocation: Randomized, Primary Purpose: Prevention

Principal Investigator

Steven J. Shiff, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Cancer Institute of New Jersey


United States: Federal Government

Study ID:




Start Date:

August 1996

Completion Date:

July 2006

Related Keywords:

  • Colorectal Cancer
  • colon cancer
  • Colonic Neoplasms
  • Colorectal Neoplasms



Rockefeller University Hospital New York, New York  10021-6399